# Theolytics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/theolytics

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.theolytics.com
- Total disclosed funding: $15M
- Latest round: Series A (Jul 1, 2021)
- Investors on record: 4

## About

Founded in 2017 and based in Oxford, UK, Theolytics Limited operates as a biotechnology company. The company was founded by its CSO, Margaret Duffy. In August 2024, Theolytics Ltd. raised GBP 2 million in grant funding from new investor Innovate UK. As of 2024, the company is led by its CEO, Charlotte Casebourne Stock.

Theolytics develops and offers next-generation oncolytic viral therapies. The company's lead product candidate, THEO-260, is a next-generation oncolytic adenovirus for the treatment of ovarian cancer.

The company plans to use the grant funding raised in August 2024 to support its Phase 1 clinical trial of THEO-260 and to establish the recommended dose for Phase 2.

## Funding rounds

- Series A, Jul 1, 2021, $5.2M — Oxford Sciences Enterprises, Taiho Ventures, M Ventures
- Series A, Dec 22, 2020, $6.8M — Epidarex Capital, Oxford Sciences Enterprises, Taiho Ventures
- Seed, Dec 19, 2017, $3.3M — Oxford Sciences Enterprises

## Investors

- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Seed, Series A
- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Series A
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series A
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A